|
1) Okamura K, Ikenoue H, Shiroozu A, et al. Reevaluation of the effects of methylmercaptoimidazole and propylthiouracil in patients with Graves' hyperthyroidism. J Clin Endocrinol Metab. 1987; 65: 719-23
|
|
|
|
2) Kallner G, Vitols S, Ljunggren JG. Comparison of standardized initial doses of two antithyroid drugs in the treatment of Graves' disease. J Intern Med. 1996; 239: 525-9
|
|
|
|
|
3) Nicholas WC, Fischer RG, Stevenson RA, et al. Single daily dose of methimazole compared to every 8 hours propylthiouracil in the treatment of hyperthyroidism. South Med J. 1995; 88: 973-6
|
|
|
|
|
|
4) Cooper DS, Goldminz D, Levin AA, et al. Agranulocytosis associated with antithyroid drugs: Effects of patient age and drug dose. Ann Intern Med. 1983; 98: 26-9
|
|
|
|
|
|
5) Tajiri J, Noguchi S. Antithyroid drug-induced agranulocytosis: How has granulocyte colony-stimulating factor (G-CSF) changed therapy？ Thyroid. 2005; 15: 292-7
|
|
|
|
|
|
6) Shiroozu A, Okamura K, Ikenoue H, et al. Treatment of hyperthyroidism with a small single daily dose of methimazole. J Clin Endocrinol Metab. 1986; 63: 125-8
|
|
|
|
|
|
7) Mashio Y, Beniko M, Ikota A, et al. Treatment of hyperthyroidism with a small single daily dose of methimazole. Acta Endocrinol (Copenh). 1988; 119: 139-44
|
|
|
|
|
|
8) Messina M, Milani P, Gentile L, et al. Initial treatment of thyrotoxic Graves'disease with methimazole: A randomized trial comparing different dosages. J Endocrinol Invest. 1987; 10: 291-5
|
|
|
|
|
|
9) Benker G, Vitti P, Kahaly G, et al. Response to methimazole in Graves' disease: The European Multicenter Study Group. Clin Endocrinol (Oxf). 1995; 43: 257-63
|
|
|
|
|
|
10) Page SR, Sheard CE, Herbert M, et al. A comparison of 20 or 40mg per day of carbimazole in the initial treatment of hyperthyroidism. Clin Endocrinol (Oxf). 1996; 45: 511-6
|
|
|
|
|
|
11) Nakamura H, Noh JY, Itoh K, et al. Comparison of methimazole and propylthiouracil in patients with hyperthyroidism caused by Graves' disease. J Clin Endocrinol Metab. 2007; 92: 2157-62
|
|
|
|
|
|
12) Momotani N, Ito K, Hamada N, et al. Maternal hyperthyroidism and congenital malformation in the offspring. Clin Endocrinol (Oxf). 1984; 20: 695-700
|
|
|
|
|
|
13) Wing DA, Millar LK, Koonings PP, et al. A comparison of propylthiouracil versus methimazole in the treatment of hyperthyroidism in pregnancy. Am J Obstet Gynecol. 1994; 170 (1 Pt 1): 90-5
|
|
|
|
|
|
14) Di Gianantonio E, Schaefer C, Mastroiacovo PP, et al. Adverse effects of prenatal methimazole exposure. Teratology. 2001; 64: 262-6
|
|
|
|
|
|
15) 荒田尚子, 守本倫子, 川城信子, 他. 妊娠初期のチアマゾール(MMI)曝露との関連が疑われる先天性奇形3例の報告. 日本内分泌学会雑誌. 2005; 81 Suppl: 37-40
|
|
|
|
|
|
16) Momotani N, Noh JY, Ishikawa N, et al. Effects of propylthiouracil and methimazole on fetal thyroid status in mothers with Graves' hyperthyroidism. J Clin Endocrinol Metab. 1997; 82: 3633-6
|
|
|
|
|
|
17) Mortimer RH, Cannell GR, Addison RS, et al. Methimazole and propylthiouracil equally cross the perfused human term placental lobule. J Clin Endocrinol Metab. 1997; 82: 3099-102
|
|
|
|
|
|
18) Tegler L, Lindstrom B. Antithyroid drugs in milk. Lancet. 1980; 2: 591
|
|
|
|
|
|
19) Kampmann JP, Johansen K, Hansen JM, et al. Propylthiouracil in human milk: Revision of a dogma. Lancet. 1980; 1: 736-7
|
|
|
|
|